Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is a promising company with a positive outlook due to its diverse pipeline of innovative immunotherapy drugs, including its lead asset givastomig, a potential treatment for gastric cancer and other gastrointestinal malignancies. The company's recent updates on givastomig and VIS-101 demonstrate their potential to become differentiated assets in the anti-VEGF market through their clinical durability and unique mechanism of action. The company's "hub-and-spoke" business model and ongoing development efforts only add to its potential upside and reinforce our confidence in its long-term success.

Bears say

NovaBridge Biosciences is experiencing financial struggles due to a net loss of $37.9M and negative cash flow from operating activities of $32.9M in the first half of 2026. Additionally, their main product, givastomig, may face challenges as it competes with similar anti-VEGF drugs and the company will need to closely monitor updates and efficacy of their drugs in larger trials. Furthermore, research efforts should focus on refining assumptions around market capture and examining the correlation between early gastritis and givastomig's efficacy.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.